The Directory of Pharma Companies and News


Servier logo
Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, oncology and diabetes, as well as by its activities in high-quality generic drugs. Entirely independent, with no shareholders, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for growth. A key player in cardiology and hypertension for the last 20 years, number 2 in Europe and 8 worldwide, Servier has 12 major products on the market with a total turnover of more than 1.6 billion euro in 2016. Currently, there are 12 new fixed-dose combinations and 10 new molecular entities in research or development, mainly targeting heart failure. This portfolio of innovative treatments is being developed with partners worldwide.
Category: Pharmaco
Category: Pharmaco

Servier News

2017-09-03Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblasti...
2017-07-02Servier announces an increase in turnover for 2015-2016
2017-06-03Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.
2017-05-01Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
2017-03-05Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting thera...
2017-03-03Servier successfully issues euro private placement
2017-01-05Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
2016-12-28OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
2016-12-07GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis
2016-11-08Servier signs agreement with non-profit association La Chaîne de l'Espoir and announces creation of the Mécénat Servier ...
2016-10-20New compound shows promise in treating multiple human cancers
2016-09-01Amgen and Servier extend Omecamtiv Mecarbil collaboration in Chronic Heart Failure
2016-08-11Servier signs agreement with non-profit association La Chaîne de l'Espoir and announces creation of the Mécénat Servier ...
2016-07-27Servier invests in bioproduction in France
2016-07-12GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis
2016-07-11Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercializ...
2016-04-27Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have a New Treatment Option as LONSURF® (trifluridine/...
2016-04-22ISHR-ES – Servier Research Fellowship 2016 awarded to Dr Hector Cabrera-Fuentes
2016-04-0640th year of operations in Brazil
2016-04-01Withdrawal of fusafungine-containing medicines from the market
2016-02-26Servier Receives Positive CHMP Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
2016-02-12EMA Benefit/Risk Revision of Fusafungine-Containing Medicines
2016-01-11Spectrum Pharmaceuticals Signs a Strategic Partnership with Servier Canada
2016-01-09Amgen and Servier extend Omecamtiv Mecarbil collaboration in Chronic Heart Failure
2015-12-18GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity In...
2015-12-07Servier announces expansion of collaboration for the development and commercialization of anticancer drug candidates tar...
2015-11-20Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier
2015-11-19Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for ...
2015-10-14Professor Félix Rey, winner of the 2015 Pasteur-Weizmann / Servier Award, for his work in the field of emerging pathogen...
2015-10-07ISHR-ES – Servier Research Fellowship 2016 / Deadline for applications: December 15, 2015
2015-10-07Horizon Discovery Group plc In-licenses Oncology Programme from Servier and Enters Option Agreement
2015-10-05Crossbeta and Servier announce strategic oligomer-based research collaboration in neurological diseases involving misfol...
2015-10-05Servier offers its expertise in industrial R&D, chemical synthesis and pharmaceutical manufacturing to partners.
2015-09-24Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical tri...
2015-08-06ISHR-ES – Servier Research Fellowship 2015 awarded to Dr Pietro Ameri
2015-08-06SERVIER Award in Microcirculation: the winners are Claudia Nussbaum and Sarah Bannenberg
2015-08-06SERVIER Research Grant in Hypertension: the winner is Dr Sébastien Foulquier
2015-07-09Cellectis Reaches Milestone in Servier Collaboration
2015-06-17VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER
2015-06-15Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Or...
2015-06-042015-2017 Winner of the UIP/Servier Fellowship
2015-04-16FDA approves ivabradine for patients with chronic heart failure
2015-04-01Servier Initiates Phase 2 Study of Gevokizumab in Patients with Diabetic Nephropathy
2015-04-01An ESCEO-IOF/Servier Achievement Award: the 2015 Pierre Delmas Prize winner is Professor Jean-Yves Reginster
2015-01-26Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors
2015-01-26FDA approval of antihypertensive Prestalia® A codevelopment by Symplmed and Servier
2014-12-15Servier, 8th European investor in the pharmaceutical sector
2014-12-04ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Musc...
2014-12-02GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of Multiple Sclerosis
2014-11-21New EMA recommendations for the use of CORLENTOR/PROCORALAN
2014-11-12Intarcia and Servier sign ex-U.S. partnership for ITCA 650 in diabetes; Intarcia retains independence & full control of ...
2014-11-06Servier Research Fellowship awarded by the Union Internationale de Phlébologie / 2015-2017 submission
2014-11-02G.B. Morgagni Prizes 2014 Winners
2014-11-02G. B. Morgagni Prizes 2014 Winners
2014-10-10SERVIER CANADA is opening its new Clinical Development Centre in Montreal, and announces a $750 000 fund at UdeM
2014-10-02Servier new research partnership with the Walter and Eliza Hall Institute to target Achilles’ heel of many cancers
2014-09-26Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration
2014-09-26EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)
2014-09-17Servier and CTI Biopharma announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI®
2014-09-01Xention and Servier commence first phase 2 study of XEN-D0103/S66913 in atrial fibrillation
2014-08-27Servier Research Grant in Hypertension
2014-08-06Vernalis and Servier achieve two Research Milestones in their Oncology Collaborations
2014-08-06Galapagos receives milestone in osteoarthritis alliance with Servier
2014-07-18Servier announces that its partner MacroGenics has initiated the first Phase 1 Study for MGD006/ S80880 for the Treatmen...
2014-07-10Servier's response to Le Monde's article (French version)
2014-07-09The European Commission limits the legitimate exercise of intellectual property rights and thus weakens the competitiven...
2014-07-09EFPIA Reaction to European Commission Decision of 9 July 2014 condemning Servier patent settlement agreements and commer...
2014-07-03Servier launches Cardiological, a mobile medical application to understand cardiovascular diseases
2014-06-23Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs...
2014-06-19Vernalis and Servier achieve Research Milestone as BCL-2 inhibitor drug candidate enters Phase I
2014-05-23The CNRS, the Universities of Montpellier 1 and 2, and SERVIER launch a research collaboration on ischemic myocardial pr...
2014-05-15Servier has compensated, is compensating and shall continue to compensate every single patient who has suffered as a res...
2014-05-13Servier enters into a global collaboration agreement for the development and the commercialization of new drugs candidat...
2014-05-08Review of ivabradine (Procoralan/Corlentor) benefit/risk ratio
2014-05-07The European Commission adopted the CHMP opinion to maintain Protelos®/Osseor® available in Europe.
2014-05-07The winner of the 2014 Jean Delay Prize is Professor Mitsumoto Sato, from Japan
2014-05-05Servier launches Pill Pro, the only pill reminder that can be used by all patients, even the oldest ones
2014-04-16Servier: one of France’s most remarkable industrial undertakings
2014-04-16Servier Research Group announces the death of President-Founder Dr. Jacques Servier
2014-04-10Press release: Servier/SAIDAL
2014-04-02IOF-SERVIER Research Grant: the 2014 winners are Charlotte Beaudart and Emmanuel Biver.
2014-04-02Pierre Delmas Prize An ESCEO-IOF/Servier Achievement Award: the 2014 winner is Professor Cyrus Cooper
2014-03-26Servier inaugurates its subsidiary in Colombia
2014-02-24Celladon Announces Option Agreement with Servier
2014-02-21The European Medicines Agency recommends that PROTELOS®/OSSEOR® remain available with further restrictions
2014-02-17Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candida...
2014-02-14Servier Canada invests $10M in two research projects supported by the Partnership Fund for an Innovative, Healthy Quebec
2014-02-05MacroGenics Achieves Milestone as Servier Exercises Option to Develop and Commercialize DARTbased Candidate, MGD006
2014-01-30Curie-Cancer and Servier renew partnership in cancer research
2014-01-20Hybrigenics achieves first research milestone for Servier
2014-01-10PROTELOS / OSSEOR: European Committee for Pharmacovigilance Recommendation
2013-11-25Servier will be partnering with Clovis Oncology, an American biopharmaceutical company, for the development of lucitanib
2013-11-08Servier's takeover bid of Egis proves successful
2013-10-04Jacques Servier ends the collaboration between Jean-Philippe Seta and Servier
2013-10-02Xention and Servier announce a cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treat...
2013-10-01The IMI diabetes platform - a new chapter in diabetes research
2013-10-01Servier Group notes Egis board announcement
2013-09-30New Winner of the UIP/Servier Research Fellowship
2013-09-24Servier Voluntary Public Purchase Offer for all outstanding shares of Egis Pharmaceuticals PFC.
2013-09-23Beijing University & Servier Cardiologist Development Foundation
2013-09-23Servier Medical Art is now licensed under Creative Commons
2013-09-19Servier partners A*STAR to develop immunity-modulating drugs to combat cancer and autoimmune diseases
2013-09-13Servier concludes a license agreement with SIMM for the development in China of lucitanib
2013-09-09SERVIER CANADA announces the creation of a new Centre of Excellence in Clinical Research
2013-08-20MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansi...
2013-08-06ISHR – Servier Research Fellowship
2013-08-06The 2013 Servier Award in Microcirculation
2013-07-30Nerviano Medical Sciences and Servier announce a Collaboration and License Agreement for a Novel Anticancer Drug
2013-07-25Galapagos delivers novel osteoarthritis molecules in alliance with Servier
2013-07-16Servier Research Grant in Hypertension
2013-07-16Pierre Delmas Prize 2013 winner
2013-07-09Amgen and Servier announce product collaboration
2013-07-03XOMA Transfers Perindopril Franchise Rights to Symplmed
2013-06-25XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program for Gevokizumab
2013-05-23miRagen Therapeutics Achieves First Milestone in Strategic Alliance with Servier
2013-04-30Afraxis, Inc. and Servier Announce a collaboration on ESP Platform for Drug Discovery in Central Nervous System Disorder...
2013-03-06Vernalis and Servier Extend Oncology Collaboration
2013-03-06Achievement of new milestones in Galapagos alliances with Servier
2013-02-20XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris
2013-01-04The UIP/Servier Research Fellowship 2013/2015 - Call for application
2012-12-03Valdoxan® (agomelatine): Award of the Italian Prix Galien 2012
2012-11-29XOMA announces Servier has initiated a proof-of-concept Gevokizumab study in patients with a history of acute coronary s...
2012-11-28Professor Caroline Dive, University of Manchester, winner of the 2012 Pasteur-Weizmann/Servier Prize
2012-11-28Servier Research Grant in Hypertension: call for application
2012-11-20G.B. Morgagni Prizes 2012 Winners
2012-11-20XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial
2012-10-27NovAliX and Servier Collaborate in Early Discovery Research Program
2012-10-10Information about Valdoxan for health care professionals
2012-10-10Information about Valdoxan for patients
2012-10-08Servier-Ruijin Talent Development and Scientific Exchanges
2012-10-08Celebrating the 10th Anniversary of Servier Tianjin Pharmaceutical Company
2012-10-03XOMA Initiates Safety and Efficacy Study of Gevokizumab in PatientXOMA Initiates Safety and Efficacy Study of Gevokizuma...
2012-10-01Servier concludes a collaboration and license agreement with EOS for its antitumor drug E-3810
2012-09-28The Florey Institute of Neuroscience and Mental Health and Servier to collaborate on a Novel Target for Alzheimer’s Dise...
2012-09-27XOMA Announces Servier has Initiated Phase 3 Gevokizumab Trial in Patients with Behçet’s Uveitis
2012-09-20Servier and MacroGenics Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products
2012-08-03Servier Announces Manufacturing Agreement with Boehringer Ingelheim
2012-07-19The winner of the 2011 Servier/UIP (Union Internationale de Phlébologie) Research Fellowship is Doctor Gy?z? SZOLNOKY
2012-07-10Renewal and extension of the collaborative contract between Servier and Genepep for the development of chemical protein ...
2012-06-29IOF-SERVIER Research Grant: the 2012 winner is Mark EDWARDS
2012-06-22The European Medicines Agency confirms the positive benefit-risk balance of Vastarel* as add-on to first line therapy in...
2012-03-07Collaboration between Servier and Monash Institute of Pharmaceutical Sciences (MIPS) on G?Protein Coupled Receptors
2012-01-12Servier and BioInvent enter Oncology collaboration
2011-12-22Servier and MacroGenics Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
2011-11-11Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
2011-11-11Servier and Hybrigenics enter into a licence and research collaboration agreement in oncology and other therapeutic fiel...
2011-11-07The Servier Award in Microcirculation 2011 winner is Dr Abigail WOODFIN
2011-11-02Servier and Miragen Sign Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting...
2011-10-18Servier exercises option on jointly-discovered Ampakine® CX1632/S 47 445, an innovative compound in clinical development...
2011-08-09Servier and Intercept Pharmaceuticals Announce Agreement in Type 2 Diabetes
2011-07-202011 Jean Delay Prize Winner: Professor Kenneth S. Kendler, USA
2011-07-07Cancer and monoclonal antibodies: “BioRéalités” acquisition by SERVIER
2011-06-21IOF-SERVIER 2012 Young Investigator Research Grant - Application information
2011-04-28Servier partners Singapore Immunology Network to develop anti-cancer drugs that nip breast cancer in the bud
2011-04-28Servier achieves a development milestone for HDAC inhibitor S-78454
2011-04-18Fondamental-Servier Grants for 2011
2011-01-25ISHR-ES SERVIER Research Fellowship 2010 awarded to Dr Atsuko KASAHARA
2011-01-18Morgagni Prizes 2010 Winners
2011-01-18The Servier Award in Microcirculation 2010 winner is Dr Jun YIN
2011-01-11ECTS/Servier Fellowship 2012 - Call for application
2011-01-06SERVIER announces Joint Development and Commercialization with XOMA on Novel Therapeutics for Orphan Disease
2010-10-25Servier and Vernalis Achieve Research Milestone in 2nd Oncology Collaboration
2010-01-24The G.B. MORGAGNI Prizes 2012 - Call for application
2009-07-20Servier reaches milestones in its osteoarthritis alliance with Galapagos
1970-01-01Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
1970-01-01Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
1970-01-01Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market
1970-01-01Dr Claude Bertrand, General Director of Research and Development at Servier
1970-01-01Servier Research Fellowship awarded by the International Union of Phlebology - Union Internationale de Phlébologie / 201...
1970-01-01Servier and Neurochlore join forces to treat autism in children
1970-01-01Cessation of marketing of Protelos/Osseor: Extract of the letter sent to European Medicine Agency (EMA) and national Eur...
1970-01-01Servier and GAIA extend their partnership to provide patients around the world with deprexis®, an internet-based cogniti...
1970-01-01Servier appoints MaSTherCell for the development of its CAR-T cell therapy manufacturing platform
1970-01-01OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
1970-01-01New compound shows promise in treating multiple human cancers
1970-01-01Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose ...
1970-01-01Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T...
1970-01-01Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness
1970-01-01Servier licenses GLPG1972 in osteoarthritis from Galapagos
1970-01-01ISHR-ES – Servier Research Fellowship 2017 awarded to Dr Vasco Sequeira Oliveira
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.